Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]
, 2018 Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core +1 more source
Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer [PDF]
Iwaho Hazekawa, Norio Ishii
openalex +1 more source
Posterior reversible encephalopathy associated with pembrolizumab
, 2021 Álvaro Lambea‐Gil +3 more
openalex +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This study investigated the impact of pretreatment nutritional status, psychological health, fatigue, and insomnia on outcomes of immune checkpoint inhibitors (ICIs) monotherapy in patients with advanced non‐small cell lung cancer (NSCLC). A total of 80 patients with stage IV NSCLC were enrolled.
Yu‐Xuan Zhu +2 more
wiley +1 more source
Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]
, 2019 PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania +6 more
core
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin +8 more
wiley +1 more source
CTIM-04. UPDATES FOR A PHASE 2 OPEN-LABELED STUDY OF PEMBROLIZUMAB PLUS TTFIELDS PLUS MAINTENANCE TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP) [PDF]
, 2020 Ashley Ghiaseddin +8 more
openalex +1 more source
Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer [PDF]
, 2021 Ivy Riaño +3 more
openalex +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted.
Yi Zhou +5 more
wiley +1 more source
Cost Effectiveness and Resource AllocationBackground Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie +6 more
doaj +1 more source